Gene Therapy (Onasemnogene Abeparvovec) Is Safe and Effective in Children with Spinal Muscular Atrophy Type 1 on Invasive Long-Term Ventilation

被引：0
|
作者：
Narayan, O. [1 ]
Alajjuri, M. [2 ]
Abusamra, R. [3 ]
Mundada, V [4 ]
机构：
[1] Amer Hosp Dubai, Pediat Pulmonol, Dubai, U Arab Emirates
[2] Univ Sharjah, Sharjah, U Arab Emirates
[3] Mediclin Hosp Dubai, Pediat Pulmonol, Dubai, U Arab Emirates
[4] Medcare Hosp Dubai, Pediat Neurol, Dubai, U Arab Emirates
来源：
PEDIATRIC PULMONOLOGY | 2023年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
H 139
引用
收藏
页码：S119 / S120
页数：2
相关论文
共 50 条
  • [21] Body of Evidence for Onasemnogene Abeparvovec in Spinal Muscular Atrophy Supports Long-Term Duration of Effect Without Relapse
    Dean, Rebecca
    Dabbous, Omar
    Weidlich, Diana
    Bischof, Matthias
    VALUE IN HEALTH, 2022, 25 (11) : 1922 - 1923
  • [22] Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec - A Single Centre Experience
    Friese, Johannes
    Geitmann, Stephanie
    Holzwarth, Dorothea
    Mueller, Nicole
    Sassen, Robert
    Baur, Ute
    Adler, Kristin
    Kirschner, Janbernd
    JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 (02) : 209 - 216
  • [23] ONASEMNOGENE ABEPARVOVEC GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY: FROM BENCH TO BEDSIDE
    Kaufmann, P.
    Kausar, I.
    Foust, K. D.
    Kaspar, A.
    Kaspar, B. K.
    Mendell, J. R.
    THORAX, 2019, 74 : A109 - A109
  • [24] Onasemnogene abeparvovec gene-replacement therapy for spinal muscular atrophy: From bench to bedside
    Kaufmann, P.
    Kausar, I.
    Foust, K. D.
    Kaspar, A.
    Kaspar, B. K.
    Mendell, J. R.
    HUMAN GENE THERAPY, 2019, 30 (08) : A9 - A9
  • [25] Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy
    Kichula, Elizabeth A.
    Proud, Crystal M.
    Farrar, Michelle A.
    Kwon, Jennifer M.
    Saito, Kayoko
    Desguerre, Isabelle
    McMillan, Hugh J.
    MUSCLE & NERVE, 2021, 64 (04) : 413 - 427
  • [26] Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1
    Finnegan, Rebecca
    Manzur, Adnan
    Munot, Pinki
    Dhawan, Anil
    Murugan, Archana
    Majumdar, Anirban
    Wraige, Elizabeth
    Gowda, Vasantha
    Vanegas, Maria
    Main, Marion
    O'Reilly, Emer
    Baranello, Giovanni
    Muntoni, Francesco
    Scoto, Mariacristina
    NEUROMUSCULAR DISORDERS, 2024, 42 : 22 - 26
  • [27] Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
    Mirea, Andrada
    Shelby, Elena-Silvia
    Axente, Mihaela
    Badina, Mihaela
    Padure, Liliana
    Leanca, Madalina
    Dima, Vlad
    Sporea, Corina
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [28] Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec
    Leon-Astudillo, Carmen
    Wagner, Mary
    Salabarria, Stephanie M.
    Lammers, Jenna
    Berthy, Julie
    Zingariello, Carla D.
    Byrne, Barry J.
    Smith, Barbara K.
    SLEEP MEDICINE, 2023, 101 : 234 - 237
  • [29] Spinal muscular atrophy type 1: Is long-term mechanical ventilation ethical?
    Ryan, Monique M.
    Kilham, Henry
    Jacobe, Stephen
    Tobin, Bernadette
    Isaacs, David
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2007, 43 (04) : 237 - 242
  • [30] Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis
    Pascual-Morena, Carlos
    Cavero-Redondo, Ivan
    Luceron-Lucas-Torres, Maribel
    Martinez-Garcia, Irene
    Rodriguez-Gutierrez, Eva
    Martinez-Vizcaino, Vicente
    HUMAN GENE THERAPY, 2023, 34 (3-4) : 129 - 138
12345